Uterine Fibroids Take Heavy Toll on Women, Survey Finds
Latest Womens Health News
THURSDAY, Oct. 10 (HealthDay News) -- Women with uterine fibroids wait more than three years on average before seeking treatment, even though symptoms often interfere with their everyday lives, a new survey finds.
These benign tumors affect up to 80 percent of women before the age of 50, and are the leading cause of hysterectomy -- surgical removal of the uterus -- in the United States.
Nearly 1,000 women with fibroids responded to the Harris Interactive survey, and close to one-third of those with jobs said they missed work because of symptoms, including heavy or prolonged menstrual bleeding, cramping and fatigue.
Many of the women expressed concern about fibroid treatment. More than three-quarters said they would prefer noninvasive approaches, more than half wanted to preserve their uterus, and younger women were often focused on preserving their fertility.
"I was impressed by how strongly women felt about uterine preservation," said study author Dr. Elizabeth Stewart, a professor of obstetrics and gynecology at the Mayo Clinic in Rochester, Minn. "For many women, even if they don't want fertility, preservation of their uterus is an important goal."
Fortunately, fibroids won't necessarily require a hysterectomy, especially if women get medical care early, she said.
The 968 women surveyed were aged 29 to 59 and had reported fibroid symptoms. Fibroids often present no symptoms, but one-quarter of women with fibroids say their day-to-day life is affected by the growths.
Among the other findings: 24 percent of the working women said fibroid symptoms kept them from reaching their career potential, and 41 percent of women saw two or more health care providers before getting a diagnosis.
A sub-study found that black women are more likely than whites to have severe symptoms, and 32 percent of black women waited more than five years before seeking medical treatment compared to 17 percent of whites.
Experts weren't surprised by the findings.
"Fibroids affect the quality of your life," said N. Edward Dourron, a reproductive endocrinologist at Hoag Memorial Hospital Presbyterian in Newport Beach, Calif. The survey results mirror what he sees and hears in real life, he said.
It's no surprise that women often see more than one doctor, said Dr. William Parker, a gynecologist at the University of California Los Angeles Medical Center, Santa Monica. "Patients get told they need a hysterectomy, and they see another doctor," he said. "And they see another doctor."
The national survey was funded by Fibroid Relief, a program of the Focused Ultrasound Foundation in Charlottesville, Va. The foundation, which promotes ultrasound treatment for fibroids, is funded by ultrasound device manufacturers such as InSightec and others, as well as private donations.
The results are published in October in the American Journal of Obstetrics and Gynecology and the Journal of Women's Health.
Stewart has been a clinical trial investigator for InSightec and a consultant for Abbott, which also contributes to the foundation, and to Gynesonics, which makes a fibroid treatment device.
The exact cause of fibroids is unknown, Stewart said. Multiple hormonal and genetic factors are believed to play a role.
Doctors disagree about the best treatments for fibroids.
"I believe treatment needs to be individualized," Stewart said. Women need to assess where they are in their reproductive lifespan. "Most women get some shrinkage [of their fibroids] at menopause," she said.
If waiting isn't an option, treatment choices include medications such as birth control pills, surgery to remove just the fibroids or hysterectomy.
Ablation, a technique that destroys the lining of the uterus, and embolization, which cuts off blood flow to the fibroid to make it shrink, are also options. Focused ultrasound, which uses ultrasound waves to destroy the fibroids, is yet another treatment.
According to Parker, "ultrasound is the least invasive approach, but it has the least amount of data." It was approved by the U.S. Food and Drug Administration in 2004.
Information on the long-term safety of focused ultrasound, including pregnancy after the ultrasound treatment, is still being collected, Stewart said.
SOURCES: Elizabeth Stewart, M.D., professor, obstetrics and gynecology, Mayo Clinic, Rochester, Minn.; N. Edward Dourron, M.D., reproductive endocrinologist, Hoag Memorial Hospital Presbyterian, Newport Beach, Calif.; William Parker, M.D., gynecologist, University of California Los Angeles Medical Center, Santa Monica, and clinical professor, obstetrics and gynecology, David Geffen School of Medicine, UCLA; October 2013 American Journal of Obstetrics and Gynecology and Journal of Women's Health